Favipiravir_Inflenza_492405
                    3D
 Structure written by MMmdl.
 14 14  0  0  1  0            999 V2000
   -2.7062    2.2286    0.0007 F   0  0  0  0  0  0
   -0.0526   -2.4378   -0.0001 O   0  0  0  0  0  0
    2.2212   -0.9191   -0.0001 O   0  0  0  0  0  0
   -2.0451   -1.3773    0.0004 N   0  5  0  0  0  0
   -0.6827    1.0927    0.0002 N   0  0  0  0  0  0
    2.0155    1.2877   -0.0000 N   0  0  0  0  0  0
   -0.0186   -0.0337    0.0001 C   0  0  0  0  0  0
   -0.7102   -1.3963    0.0001 C   0  0  0  0  0  0
   -2.7073   -0.1426    0.0006 C   0  0  0  0  0  0
   -2.0536    1.0466    0.0005 C   0  0  0  0  0  0
    1.4731    0.0588   -0.0000 C   0  0  0  0  0  0
   -3.7872   -0.1628    0.0009 H   0  0  0  0  0  0
    3.0183    1.4002   -0.0000 H   0  0  0  0  0  0
    1.4195    2.1026   -0.0000 H   0  0  0  0  0  0
  1 10  1  0  0  0
  2  8  2  0  0  0
  3 11  2  0  0  0
  4  9  1  0  0  0
  4  8  1  0  0  0
  5  7  2  0  0  0
  5 10  1  0  0  0
  6 11  1  0  0  0
  6 13  1  0  0  0
  6 14  1  0  0  0
  7  8  1  0  0  0
  7 11  1  0  0  0
  9 10  2  0  0  0
  9 12  1  0  0  0
M  CHG  1   4  -1
M  END
> <s_m_entry_id>
28

> <s_m_entry_name>
Favipiravir2D_Inflenza_492405.1

> <PUBCHEM_COMPOUND_CID>
492405

> <PUBCHEM_COMPOUND_CANONICALIZED>
1

> <PUBCHEM_CACTVS_COMPLEXITY>
282

> <PUBCHEM_CACTVS_HBOND_ACCEPTOR>
4

> <PUBCHEM_CACTVS_HBOND_DONOR>
2

> <PUBCHEM_CACTVS_ROTATABLE_BOND>
1

> <PUBCHEM_CACTVS_SUBSKEYS>
AAADcYBjMQAAAAAAAAAAAAAAAAAAAAAAAAAgAAAAAAAAAAAAAAAAHwAQAAAACAjBgAQAAALAAACoAQE2VAAAAAAAAgAAAIEIAAAAAAgIQAAEAAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA==

> <PUBCHEM_IUPAC_OPENEYE_NAME>
5-fluoro-2-oxo-1H-pyrazine-3-carboxamide

> <PUBCHEM_IUPAC_CAS_NAME>
5-fluoro-2-oxo-1H-pyrazine-3-carboxamide

> <PUBCHEM_IUPAC_NAME_MARKUP>
5-fluoro-2-oxo-1<I>H</I>-pyrazine-3-carboxamide

> <PUBCHEM_IUPAC_NAME>
5-fluoro-2-oxo-1H-pyrazine-3-carboxamide

> <PUBCHEM_IUPAC_SYSTEMATIC_NAME>
5-fluoranyl-2-oxidanylidene-1H-pyrazine-3-carboxamide

> <PUBCHEM_IUPAC_TRADITIONAL_NAME>
5-fluoro-2-keto-1H-pyrazine-3-carboxamide

> <PUBCHEM_IUPAC_INCHI>
InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)

> <PUBCHEM_IUPAC_INCHIKEY>
ZCGNOVWYSGBHAU-UHFFFAOYSA-N

> <PUBCHEM_XLOGP3_AA>
-0.6

> <PUBCHEM_EXACT_MASS>
157.028755

> <PUBCHEM_MOLECULAR_FORMULA>
C5H4FN3O2

> <PUBCHEM_MOLECULAR_WEIGHT>
157.1

> <PUBCHEM_OPENEYE_CAN_SMILES>
C1=C(N=C(C(=O)N1)C(=O)N)F

> <PUBCHEM_OPENEYE_ISO_SMILES>
C1=C(N=C(C(=O)N1)C(=O)N)F

> <PUBCHEM_MONOISOTOPIC_WEIGHT>
157.028755

> <PUBCHEM_TOTAL_CHARGE>
0

> <PUBCHEM_HEAVY_ATOM_COUNT>
11

> <PUBCHEM_ATOM_DEF_STEREO_COUNT>
0

> <PUBCHEM_ATOM_UDEF_STEREO_COUNT>
0

> <PUBCHEM_BOND_DEF_STEREO_COUNT>
0

> <PUBCHEM_BOND_UDEF_STEREO_COUNT>
0

> <PUBCHEM_ISOTOPIC_ATOM_COUNT>
0

> <PUBCHEM_COMPONENT_COUNT>
1

> <PUBCHEM_CACTVS_TAUTO_COUNT>
-1

> <PUBCHEM_COORDINATE_TYPE>
1
5
255

> <PUBCHEM_BONDANNOTATIONS>
4  8  8
4  9  8
5  10  8
5  7  8
7  8  8
9  10  8

> <chiral flag>
1

> <version>
0

> <s_m_Source_Path>
E:\Projects\DeepLearning\Drug\CORONA\Ligand2D

> <s_m_Source_File>
Favipiravir2D_Inflenza_492405.sdf

> <i_m_Source_File_Index>
1

> <PUBCHEM_CACTVS_TPSA>
84.6

> <chiral flag>
0

> <s_m_source_file>
ligprep_10.maegz

> <i_m_source_file_index>
8

> <i_lp_mmshare_version>
44012

> <i_f3d_flags>
0

> <s_epik_input>
Tz1DKFtOSDJdKWMxbmMoRilbY0hdW25IXWMxPU8=

> <s_epik_cmdline>
J2VwaWtfcHl0aG9uJywgJy1waCcsICc3LjAnLCAnLXRuJywgJzgnLCAnLW1hJywgJzIwMCcsICctaW1hZScsICc8aW5maWxlLm1hZT4nLCAnLW9tYWUnLCAnPG91dGZpbGUubWFlPic=

> <r_epik_Ionization_Penalty>
  0.0009

> <r_epik_Ionization_Penalty_Charging>
  0.0005

> <r_epik_Ionization_Penalty_Neutral>
  0.0004

> <r_epik_State_Penalty>
  0.0098

> <r_epik_Charging_Adjusted_Penalty>
0.0102484

> <i_epik_Tot_Q>
-1

> <i_epik_Tot_abs_Q>
1

> <s_lp_Force_Field>
OPLS3e

> <r_lp_Energy>
50.7929

> <b_lp_Chiralities_Consistent>
1

> <s_lp_Variant>
Favipiravir2D_Inflenza_492405-1

> <s_m_job_name>
ligprep_10

> <r_lp_tautomer_probability>
1

> <s_m_subgroupid>
ligprep_10-out1

> <s_m_subgroup_title>
ligprep_10-out1

> <b_m_subgroup_collapsed>
0

$$$$
